Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits

Annals of Clinical Biochemistry

Volumn 50, Issue 1, 2013, Pages 53-61

  Whitehead, S J ^a   French, J ^b   Brookes, M J ^a   Ford, C ^a   Gama, R ^a,c  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b Institute of Research and Development   (United Kingdom)

^c UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; FECAL CALPROTECTIN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; ELISA KIT; EXTRACTION; FECES ANALYSIS; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEDICAL DEVICE; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; STOOL EXTRACTION DEVICE;

BIOLOGICAL MARKERS; CALIBRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; LIMIT OF DETECTION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 84880302180     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2012.011272     Document Type: Article

References (47)

1. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl. 5):v1-v16
2. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94
3. Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology 2004;126:1561-73
4. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2007;2:1-32
5. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-21
6. Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985;84:24-34
7. Fagerhol MK, Anderson KB, Naess-Andresen CF, Brandtaeg P, Dale I. Calprotectin (the L1 leukocyte protein). In: Smith VL, Dedman JR, eds. In: Stimulus Response Coupling: the Role of Intracellular Calcium Binding Proteins. Boca Raton, FL, USA: CRC Press Inc., 1990;187-210
8. Corbin BD, Seeley EH, Raab A, et al. Metal chelation and inhibition of bacterial growth in tissue abscesses. Science 2008;319:962-5
9. Lulloff S, Hahn B, Sohnle P. Fungal susceptibility to zinc deprivation. J Lab Clin Med 2004;144:208-14
10. McNamara MP, Weissner JH, Collins-Lech C, Hahn BL, Sohnle PG. Neutrophil death as a defence mechanisms against Candida albicans infections. Lancet 1988;2:1163-5
11. Nisapakultorn K, Ross K, Herzberg MC. Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect Immun 2001;69:3692-6
12. Santhanagopalan V, Hahn B, Dunn B, Weissner JH, Sohnle PG. Antimicrobial activity of calprotectin isolated from human empyema fluid. Clin Immunol Immunopathol 1995;76:285-90
13. Sohnle P, Hahn B, Santhanagopalan V. Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms. J Infect Dis 1996;174:1369-72
14. Sohnle PG, Collins-Lech C, Weissner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abcess fluid supernatants. J Infect Dis 1991;164:137-42
15. Hashemi M, Chitayat S, Ande SR, Chazin WJ. Apoptosis-inducing activity of the S100A8/A9 heterodimer. Anti-Inflamm Anti-Allergy Agents Med Chem 2009;8:318-28
16. Zali H, Marashi SA, Rezaei-Tavirani M, Toossi P, Rahmati-Roodsari M, Shokrgozar MA. On the mechanism of apoptosis-inducing activity of human calprotectin: zinc sequestration, induction of a signaling pathway, or something else? Med Hypotheses 2007;68:1012-5
17. Zali H, Rezaei-Tavirani M, Kariminia A, Yousefi R, Shokrgozar MA. Evaluation of growth inhibitory and apoptosis inducing activity of human calprotectin on the human gastric cell line (AGS). Iranian Biomed J 2008;12:7-14
18. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein called calprotectin. J Clin Pathol Mol Pathol 1997;50:113-23
19. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003;170:3233-42
20. Sorg C. The calcium binding proteins MRP8 and MRP14 in acute and chronic inflammation. Behringer Inst Mitt 1992;91:126-37
21. Pouliss A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:675-81
22. Angriman I, Scarpa M, D'Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381:63-8
23. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008;51:1283-91
24. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastro 2007;102:803-13
25. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66
26. Meucci G, D'Incà R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig Liver Dis 2010;42:191-5
27. Centre for Evidence-based Purchasing. Value of Calprotectin in Screening out Irritable Bowel Syndrome: Evidence Review. London: NHS Purchasing and Supply Agency, 2010:CEP09026
28. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369
29. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4
30. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13
31. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Gastroenterology 1990;98:811-8
32. Saverymuttu SH. Clinical remission in Crohn's disease-assessment using faecal111In granulocyte excretion. Digestion 1986;33:74-9
33. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9
34. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009;96:663-74
35. Kasier T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2010;56:1706-13
36. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60
37. Joshi S, Lewis SJ, Creanor S, Ayling R. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010;47:259-63
38. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8
39. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:119-22
40. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20
41. Sipponen A, Savilahti E, Kärkkaïnen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-8
42. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces-a methodologic study. Scand J Gastroenterol 1992;27:793-8
43. Tøn H, Brandsnes Ø, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54
44. Armbuster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 2008;29(Suppl. (i)):S49-S52
45. Bühlmann Calprotectin ELISA kit insert, ref: EK-CAL. Revision date: 05-06-2011. Schönenbuch, Switzerland: Bühlmann Laboratories, 2011
46. Eurospital Calprest kit insert, ref: 9031. Revision date: 30-05-2005. Trieste, Italy: Eurospital, 2005
47. Immunodiagnostik PhiCal Calprotectin ELISA kit insert, ref: K6937. Revision date: 19-01-2009. Bensheim, Germany: Immunodiagnostik, 2009